Frequently Asked Questions
It looks like the previous grant DP15-1512 was similar to this one. I was wondering who the awardees were to that grant.
There was one awardee to that grant and that was the National Association of Chronic Disease Directors.
I noticed that between the two NOFOs from DP15-1512 and this one the eligibility has changed and now includes state governments. I was wondering if there’s any alteration in the expectations of the outcomes now that you are considering state government to be an eligible applicant.
The policy of the Federal Health and Human Services is that we have open competition. So there are state governments who are eligible, there are city governments, there are 501C3’s. It’s a wide variety of organizations that are eligible for this particular funding opportunity. We have stated the expected outcomes for this NOFO. That hasn’t changed regardless of who would be successful in receiving this opportunity.
My question is around the evaluation component. When I was reading the direction for the grant it was very specific that research cannot be included. So I wondered if your group could talk us through kind of that line between research and evaluation and how to basically ensure that we’re answering evaluation components of the grant thoroughly.
In terms of what this is about. This is not a research NOFO. This is not a research funding opportunity to be able to prove research is valid or invalid. This is looking at the practice of chronic disease prevention and improving the skills, the experience, the capabilities of the leadership as well as the workforce of state chronic disease prevention programs. It’s also looking at trying to figure out the best way to translate practice, chronic disease and intervention practice into the kinds of evidence that we need to fuel the appropriate interventions to move chronic disease prevention forward. It’s taking it from the practice to evidence as opposed to trying to develop evidence within a clinical setting.
So just to make sure that I understand that fully and correctly. So just if we are thinking about the leadership piece, would one appropriate approach to measuring effective leadership of those that are trained in this project be for example to use a measure that looks at effective leadership? Would that be appropriate within the scope of evaluation?
I think it would be appropriate within the scope of evaluation if that leadership measurement actually measured implementation and impact of chronic disease prevention programs.
The RFA discusses providing training and education for Chronic Disease staff in state health departments. I wanted to know more about the scope of this. Are awardees expected to address any specific chronic disease(s), all chronic diseases, or somewhere in between?
The recipient is expected to support strengthening the leadership and expertise in chronic disease prevention for state chronic disease prevention and health promotion staff, which may include specific chronic diseases or may require addressing all chronic diseases. In addition, the recipient is expected to develop trainings that will build leadership skills and competencies of state chronic disease prevention and health promotion staff.
Are awardees expected to work with all state health departments in the U.S., or just a subset of states?
The recipient is expected to work with all state health departments in the U.S.
For the purposes of this RFA, is substance abuse considered a chronic disease?
Substance abuse is not included as a chronic disease for funding opportunity CDC-RFA-DP18-1814, National Organization for Chronic Disease Prevention and Health Promotion.
Is this a continuation of previous work, and if so, could you tell me who had the assignment?
This Notice of Funding Opportunity builds on previous work that we have undertaken to strengthen the capacity of state chronic disease prevention program directors and staff to develop and implement effective chronic disease prevention programs. Over the last three years, the National Association of Chronic Disease Directors has initiated efforts under DP15-1512.
Is having key staff with the experience with the target audience sufficient to meet the experience requirement?
Please refer to a more complete description of the organizational capacity to implement the approach in the NOFO, starting on page 9. There is a great deal of information to describe what this NOFO requires in terms of experience. You may also wish to review the “Applicant’s Organizational Capacity to Implement the Approach” elements in the Review and Selection Process section starting on page 25.
Could you confirm that the National Association of Chronic Disease Directors was the recipient?
Yes, the National Association of Chronic Disease Directors was the recipient of CDC-RFA-DP15-1512.
Could you also confirm that this new RFA must have a national reach in the training, TA, and services the recipient provides?
The recipient is expected to work with all state health departments in the U.S. to provide training and technical assistance and to implement workforce development strategies and activities.
I am interested in learning more about this program, specifically whether the Health Promotion and Disease Prevention Research Center opportunities typically come up every year or only once every 5 years.
CDC-RFA-DP18-1814 is a non-research funding opportunity that will be funded September 30, 2018-September 29, 2023 contingent on the availability of funds as described in the Award Information section of the notice of funding opportunity. While the programmatic funding opportunity is described with a project period of 5 years, funding is allocated on a 1-year basis.
For more information on CDC-RFA-DP19-001, Health Promotion and Disease Prevention Research Centers, please visit: https://www.cdc.gov/chronicdisease/about/foa/prcs/index.htm.
I am interested to learn about how many programs were funded in the past five years.
There was one recipient of the previous award, CDC-RFA-DP15-1512, which was funded for three years.
Going forward what are these funding levels expect to continue past this call? If they are every year, can we expect another cycle of these type of grants in 2019?
The approximate total fiscal year funding is $3,000,000. The approximate period of length is five years. Please refer to the Award Information section for additional details.
I checked grants.gov to see if a list would be posted with names/institutions of callers on last week’s synopsis call & I did not see it there. Would you be able to share that information & also indicate approximately how many LOI you received for the CD workforce development & leadership training cooperative agreement opportunity?
We will post the transcript of the informational call on our website, https://www.cdc.gov/chronicdisease/about/foa/chronic-disease/index.htm. Submission of a letter of intent was optional; we ask for a LOI in order to estimate the number of objective reviewers this NOFO will require. One letter of intent was received by the May 8, 2018 deadline.
Has there been a change in the direction or scope of this effort?
This Notice of Funding Opportunity builds on previous work that we have undertaken to strengthen the capacity of state chronic disease prevention program directors and staff to develop and implement effective chronic disease prevention programs. This announcement complements work implemented in CDC-RFA-DP15-1512. The strategies, activities, and expected outcomes for funding opportunity DP18-1814 have been detailed in the announcement.
- Page last reviewed: May 18, 2018
- Page last updated: May 18, 2018
- Content source: